Clinical Trial Update: GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 2/3 study of GBS-NN and GBS-NN2 fusion proteins with Alhydrogel, given with and without the Tdap vaccine in healthy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Group Streptococcal Infection

Drugs mentioned

• Alhydrogel (Aluminum hydroxide adjuvant)
• GBS-NN (GBS-NN fusion protein)
• GBS-NN2 (GBS-NN2 fusion protein)
• Tdap vaccine (Diphtheria, tetanus, and pertussis vaccine (Tdap))

Snippet

Sponsor: Minervax ApS | Conditions: Streptococcus Agalactiae Infection | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING